Patents Represented by Attorney Richard F. Flehr Hohbach Test Albritton & Herbert LLP Trecartin
  • Patent number: 6156729
    Abstract: A method for inhibiting and/or reducing inflammation and/or pain in an individual is provided. The method comprises administration of leukemia inhibitory factor (LIF) to a cell or an individual in an amount effective to inhibit and/or reduce inflammation and/or pain.
    Type: Grant
    Filed: October 15, 1998
    Date of Patent: December 5, 2000
    Assignee: California Institute of Technology
    Inventors: Paul H. Patterson, Clifford J. Woolf
  • Patent number: 6140058
    Abstract: A class of mutant forms of p53 protein, such as His273 and Lys285, which are defective in conversion from the latent to the activated state by casein kinase II, but with the ability to be activated for specific DNA binding by the action of ligands such as monoclonal antibody PAb421 and heat shock protein DnaK. Activation of these mutants, which are found at high levels in certain types of tumour, can potentially lead to selective growth arrest and induction of apoptosis in the tumor cells. p53 can be constitutively activated also by deletion of the C-terminal 30 amino acids. p53 activated in this way, or by ligand binding, can be administered for the purposes of tumour or cell growth suppression.
    Type: Grant
    Filed: July 24, 1995
    Date of Patent: October 31, 2000
    Assignee: Newburn Ellis
    Inventors: David Philip Lane, Theodore Robert Hupp
  • Patent number: 6140072
    Abstract: Novel polymers are provided which are produced by recombinant techniques. The polymers are characterized by having a small repeating sequence which provides for strands capable of associating, resulting in useful structural characteristics, where the strands are joined by turns or loops which are flexible and available for interaction with the environment. Specifically, repeating groups of naturally occurring proteins such as silk are modified by introduction of an amino-acid sequence at a site which provides for a turn between strands to provide for readily available oligopeptides capable of interacting with molecules in the environment.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 31, 2000
    Assignee: Protein Polymer Technologies, Inc.
    Inventors: Franco A. Ferrari, Joseph Cappello
  • Patent number: 6103490
    Abstract: Novel vectors are disclosed for expressing and secreting heterologous polypeptides from filamentous fungi. Such vectors are used in novel processes to express and secrete such heterologous polypeptides. The vectors used for transforming a filamentous fungus to express and secrete a heterologous polypeptide include a DNA sequence encoding a heterologous polypeptide and a DNA sequence encoding a signal sequence which is functional in a secretory system in a given filamentous fungus and which is operably linked to the sequence encoding the heterologous polypeptide. Such signal sequences may be the signal sequence normally associated with the heterologous polypeptides or may be derived from other sources. The vector may also contain DNA sequences encoding a promoter sequence which is functionally recognized by the filamentous fungus and which is operably linked to the DNA sequence encoding the signal sequence.
    Type: Grant
    Filed: June 17, 1994
    Date of Patent: August 15, 2000
    Assignee: Genencor International, Inc.
    Inventors: Randy Michael Berka, Daniel Cullen, Gregory Lawrence Gray, Kirk James Hayenga, Virgil Bryan Lawlis
  • Patent number: 6045798
    Abstract: Nucleic acid encoding four novel immunodeterminant protein antigens of M. bovis BCG, which is a vaccine strain for tuberculosis, have been isolated. These genes were isolated as immunoreactive recombinant clones from a genomic library of M. bovis BCG DNA, constructed in pBR322 vector, and screened with sera collected from tuberculosis patients. The BCG DNA insert of one of the recombinants, pMBB51A, which expressed an antigen of Mr 90 kD, was sequenced completely and an ORF encoding 761 amino acids encoding a protein of deduced molecular weight 79 kD, was identified. This gene was identified to encode a membrane bound, ion-motive ATPase of M. bovis BCG. The approach described here can be used to identify immunogens of mycobacteria. In addition, the well-characterized M. bovis BCG antigens can be used in the prevention, diagnosis and treatment of tuberculosis. The 79 kD antigen is also useful in the design of recombinant vaccines against different pathogens.
    Type: Grant
    Filed: June 18, 1998
    Date of Patent: April 4, 2000
    Inventors: Archana Kapoor, Anil Munshi
  • Patent number: 6033654
    Abstract: Proteinaceous polymers having repetitive units from naturally occurring structural proteins are employed as backbones for functionalities for crosslinking to provide strongly adherent tissue adhesives and sealants. Particularly, block copolymers having repeating units of elastin and fibroin are employed having lysine substitutions in spaced apart units, where the amino group can be crosslinked using difunctional crosslinking agents. The protein polymer contains at least 40 weight percent of repetitive units of 3 to 30 amino acids of at least one naturally occurring structural protein and at least two functional groups capable of reacting with a crosslinking agent to form a strongly adherent adhesive composition for bonding together separated tissue or for sealing tissue defects.
    Type: Grant
    Filed: May 2, 1996
    Date of Patent: March 7, 2000
    Assignee: Protein Polymer Technolgies, Inc.
    Inventors: Erwin R. Stedronsky, Joseph Cappello
  • Patent number: 6034220
    Abstract: Highly repetitive proteins which are relatively insoluble in water are chemically modified to increase solubility. The protein is reacted with a functionalizing agent to introduce additional polar functionalities and disrupt the order of the protein. The solubility of the protein in water is increased by the chemical modification, while adhesive and surfactant properties are retained.
    Type: Grant
    Filed: February 23, 1998
    Date of Patent: March 7, 2000
    Assignee: Protein Polymer Technologies
    Inventor: Erwin R. Stedronsky
  • Patent number: 6018030
    Abstract: Polypeptides comprising repetitive units of amino acids, as well as synthetic genes encoding the subject polypeptides are provided. The subject polypeptides are characterized by comprising repetitive units of amino acids, where the repetitive units are present in naturally occurring proteins, particularly naturally occurring structural proteins. The subject polypeptides find use in a variety of applications, such as structural components of prosthetic devices, synthetic fibers, and the like.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 25, 2000
    Assignee: Protein Polymer Technologies, Inc.
    Inventors: Franco A. Ferrari, Charles Richardson, James Chambers, Stuart Causey, Thomas J. Pollock, Joseph Cappello, John W. Crissman
  • Patent number: 6015474
    Abstract: The present invention concerns novel methods for enhancing the mechanical performance of tissue adhesives and sealants which comprises employing a primer molecule in association with a tissue adhesive or sealant, wherein the primer molecule serves to enhance the strength of the interface between the tissue and the adhesive matrix. The primer molecules described herein function to interact with collagen present in the tissue, thereby altering its characteristics to make it more amenable to bonding with the adhesive matrix. Primer molecules may be applied to the tissue independently from the tissue adhesive or sealant or may be mixed with the tissue adhesive or sealant prior to application to the tissue.
    Type: Grant
    Filed: June 20, 1997
    Date of Patent: January 18, 2000
    Assignee: Protein Polymer Technologies
    Inventor: Erwin R. Stedronsky
  • Patent number: 6011139
    Abstract: Isolated polypeptides useful in ameliorating GAD-associated autoimmune disease as well as diagnostic and therapeutic methods of using the peptides are disclosed. Monoclonal antibodies specific for GAD peptides and hybridoma cells producing such are also disclosed.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 4, 2000
    Assignee: The Regents of the University of California
    Inventors: Allan J. Tobin, Mark G. Erlander, Daniel L. Kaufman
  • Patent number: 5998366
    Abstract: Isolated polypeptides useful in ameliorating GAD-associated autoimmune disease as well as diagnostic and therapeutic methods of using the peptides are disclosed.
    Type: Grant
    Filed: April 9, 1997
    Date of Patent: December 7, 1999
    Assignee: The Regents of the University of California
    Inventors: Allan J. Tobin, Mark G. Erlander, Daniel L. Kaufman
  • Patent number: 5981494
    Abstract: The present invention is directed to the use of glycosidase inhibitors for inhibiting the conversion of a pro-toxin to a toxin by a glycosidase enzyme. In particular, the present invention relates to the use of glycosidase inhibitors for the treatment of malaria, endotoxic shock or septic shock.
    Type: Grant
    Filed: August 27, 1998
    Date of Patent: November 9, 1999
    Assignee: University College London
    Inventors: Thomas Rademacher, John Playfair, Hugo Caro, Janice Taverne, Nadeem Sheikh
  • Patent number: 5962019
    Abstract: Improved oral cyclosporin formulations which have high bioavailability and are capable of administration in both liquid and hard capsule form are provided. In the subject formulations, cyclosporin is delivered in an orally acceptable vehicle comprising at least one alkanol solvent of from 2 to 3 carbon atoms in combination with at least one non-ionic surfactant. The subject formulations may further comprise at least one cosolvent, where cosolvents of interest include fatty acids and diols. The subject formulations find use in immuno-suppressive therapy.
    Type: Grant
    Filed: October 23, 1997
    Date of Patent: October 5, 1999
    Assignees: SangStat Medical Corporation, University of North Carolina at Chapel Hill
    Inventors: Moo J. Cho, Ralph E. Levy, Philippe J. Pouletty
  • Patent number: 5922548
    Abstract: Compounds and libraries are labeled with a galactosyl epitope and then screened in accordance with an assay involving cells having a characteristic of interest. Conveniently, the screening may embody target cells, where the compounds are brought in contact with the cells. Each of the compounds carries with it the information of its identity or method of synthesis. After washing away non-specifically bound compounds, blood may be applied to the cells, whereby antibody binding to the galactosyl epitope initiates the complement cascade. Plaques are identified and the compound associated with the plaque identified. The formation of the plaque demonstrates that the compound has specific affinity for the target cell, binding of the compound to the cell does not interfere with binding of the antibody, and that the complex is capable of cytotoxic activity by means of the complement cascade.
    Type: Grant
    Filed: October 2, 1997
    Date of Patent: July 13, 1999
    Assignee: SangStat Medical Corporation
    Inventors: Alexander R. Lussow, Roland Buelow, Philippe Pouletty
  • Patent number: 5891726
    Abstract: The present invention includes novel methods for increasing the seed productivity or accelerating the growth rate of a plant and plants produced by such methods. Such plants have at least one cell transformed with an expression complex comprising a promoter operably linked to a gene encoding a pyruvate phosphate dikinase which is capable of converting pyruvate into phosphoenolpyruvate. The plants are made by transforming at least one plant cell with an appropriate expression construct, regenerating plants from one or more transformed plant cells and selecting at least one plant having the desired phenotype.
    Type: Grant
    Filed: August 28, 1996
    Date of Patent: April 6, 1999
    Inventor: Ahmed Sheriff
  • Patent number: 5885432
    Abstract: Electrophoretic media are provided comprising at least un-crosslinked polymers which have a temperature reversible transition from low viscosity to high viscosity, so as to be pourable at one temperature, while providing sieving properties at another temperature. Optionally included with the un-crosslinked polymers having a reversible temperature responsive viscosity change are gelling agents and polymers which do not have the reversible temperature responsive viscosity change. The subject compositions have excellent clarity, provide excellent separation and resolution, handling properties, and mechanical strength. The compositions are compatible with transfer of separated components from the gel to an accepting membrane.
    Type: Grant
    Filed: January 22, 1996
    Date of Patent: March 23, 1999
    Assignee: Soane BioSciences
    Inventors: Herbert H. Hooper, Alexander P. Sassi, David S. Soane, Young Bae
  • Patent number: 5773577
    Abstract: Polymers are provided comprising protein polymers comprising blocks of repeating units and sequences comprising amino acids, individually or in defined sequences, capable of enzyme catalyzed covalent bond formation for cross-linking, as exemplified by glutamine and/or lysine reactive for FXIII catalyzed isopeptide formation or non-amino acid polymers having side chains comprising such amino acids or sequences, which may be used for preparation of articles of manufacture, particularly cross-linkable compositions. By appropriate choice of the polymer, resorbable implantable polymers may be used in internal applications for mammals as formed objects or depots.
    Type: Grant
    Filed: March 2, 1995
    Date of Patent: June 30, 1998
    Assignee: Protein Polymer Technologies
    Inventor: Joseph Cappello
  • Patent number: 5741924
    Abstract: Novel polymeric compositions and their intermediates are provided, providing for broad range protection from ultraviolet radiation. Acryl polymers comprising at least two different ultraviolet absorbing moieties having different light absorbing ranges are employed in conjunction with another hydrophilic monomer to provide sunscreen formulations for invisibility, and enhanced protection, without deleterious effects in the dermis.
    Type: Grant
    Filed: June 14, 1995
    Date of Patent: April 21, 1998
    Assignee: Biophysica Inc.
    Inventors: Milos Sovak, Ronald Calvin Terry, James Gordon Douglass, III, Farid Bakir
  • Patent number: 5689055
    Abstract: The invention includes transformed plants having at least one cell transformed with a modified ETR nucleic acid. Such plants have a phenotype characterized by a decrease in the response of at least one transformed plant cell to ethylene as compared to a plant not containing the transformed plant cell. Tissue and/or temporal specificity for expression of the modified ETR nucleic acid is controlled by selecting appropriate expression regulation sequences to target the location and/or time of expression of the transformed nucleic acid. The plants are made by transforming at least one plant cell with an appropriate modified ETR nucleic acid, regenerating plants from one or more of the transformed plant cells and selecting at least one plant having the desired phenotype.
    Type: Grant
    Filed: September 19, 1995
    Date of Patent: November 18, 1997
    Assignee: California Institue of Technology
    Inventors: Elliott M. Meyerowitz, Caren Chang, Anthony B. Bleecker
  • Patent number: 5652136
    Abstract: Novel enzyme mutants are disclosed which are derived from a precursor enzyme by replacing or modifying at least one catalytic functional group of an amino acid residue in a precursor enzyme. Such mutant enzymes have a catalytic preference for substrates which provide the replaced or modified catalytic group or its equivalent such that the substrate together with the enzyme mutant assists in its own catalysis.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 29, 1997
    Assignee: Genencor International, Inc.
    Inventors: Paul John Carter, James Allen Wells